NFE2L2 and osteoporosis: Similarly, Poudel et al. [37] found that resveratrol inhibits osteoclast differentiation in doxorubicin-induced osteoporosis by enhancing antioxidant pathways, such as upregulating Sod1 and NRF2, and downregulating osteoclast markers like RANK and TRAP.